The expression of NKG2D ligands (NKG2DLs), induced by stress or malignant transformation, is considered to mark dysfunctional cells for elimination by NK cells or cytotoxic lymphocytes via NKG2D/NKG2DLs pathway. ULBP1, ULBP2, and ULBP3 (ULBP1-3), three members of NKG2DLs, are common expressed in breast cancer. We analyzed the expression of ULBP1-3 in breast cancer and healthy control tissues with several databases, and found that breast cancer had a higher mRNA level of ULBP1 and ULBP2, and a higher protein level of ULBP1-3. Analysis with the bc-GenExMiner database showed that the expression of ULBP1-3 were down-regulated by the wild type P53, PR, and HER2+ in breast cancer. Except for ULBP1, ULBP2 and ULBP3 were associated with poor prognosis in breast cancer. The analysis of the correlated genes suggested that ULBP1-3 have some common pathways including NK cell-mediated cytotoxicity, microRNA in cancer, and IL-17 signaling pathway, whereas they also have their own pathways. But ULBP1-3 expression were also a significantly negative correlation with few immune markers on NK and central memory CD8+ T. The correlations and co-occurrence between ULBP1-3 and the other ligands by using TIMER and cbioportal databases showed the same form proteins or the proteins in the same family were more likely to change at the same time. Together with all these findings, increased ULBP2 and ULBP3 were correlated with poor prognosis and various markers on immune cells. These conclusions indicated that ULBP2 and ULBP3 could serve as potential biomarkers to assess prognosis and they were strong correlation with various markers in immune cells.